Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Bicara Therapeutics Inc’s stock clocked out at $17.31, down -6.48% from its previous closing price of $18.51. In other words, the price has decreased by -$6.48 from its previous closing price. On the day, 0.91 million shares were traded. BCAX stock price reached its highest trading level at $18.19 during the session, while it also had its lowest trading level at $16.512.
Ratios:
To gain a deeper understanding of BCAX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 25.80 and its Current Ratio is at 25.80. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $36.
On May 23, 2025, Wells Fargo Upgraded its rating to Equal Weight which previously was Underweight but kept the price unchanged to $8.
On April 17, 2025, Wells Fargo started tracking the stock assigning a Underweight rating and target price of $8.Wells Fargo initiated its Underweight rating on April 17, 2025, with a $8 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 13 ’25 when Mazumdar Claire bought 11,445 shares for $18.92 per share.
Raben David sold 22,000 shares of BCAX for $405,900 on Oct 09 ’25. The Chief Medical Officer now owns 35,497 shares after completing the transaction at $18.45 per share. On Oct 09 ’25, another insider, Hyep Ivan, who serves as the Chief Financial Officer of the company, sold 6,415 shares for $18.23 each. As a result, the insider received 116,931 and left with 145,355 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCAX now has a Market Capitalization of 1010876864 and an Enterprise Value of 510114784.
Stock Price History:
The Beta on a monthly basis for BCAX is -0.98, which has changed by -0.14306933 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, BCAX has reached a high of $28.09, while it has fallen to a 52-week low of $7.80. The 50-Day Moving Average of the stock is 35.66%, while the 200-Day Moving Average is calculated to be 38.46%.
Shares Statistics:
It appears that BCAX traded 416.40K shares on average per day over the past three months and 656250 shares per day over the past ten days. A total of 54.56M shares are outstanding, with a floating share count of 30.98M. Insiders hold about 43.27% of the company’s shares, while institutions hold 64.05% stake in the company. Shares short for BCAX as of 1759190400 were 5457251 with a Short Ratio of 13.11, compared to 1756425600 on 5392258. Therefore, it implies a Short% of Shares Outstanding of 5457251 and a Short% of Float of 15.630000999999998.
Earnings Estimates
Its stock is currently analyzed by 8.0 different market analysts. The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.37 and low estimates of -$0.69.
Analysts are recommending an EPS of between -$1.91 and -$2.43 for the fiscal current year, implying an average EPS of -$2.22. EPS for the following year is -$2.45, with 8.0 analysts recommending between -$1.88 and -$3.01.
